Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial

Published:2021-10 Issue:10 Volume:22 Page:1458-1467
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Del Mastro Lucia,Mansutti Mauro,Bisagni Giancarlo,Ponzone Riccardo,Durando Antonio,Amaducci Laura,Campadelli Enrico,Cognetti Francesco,Frassoldati Antonio,Michelotti Andrea,Mura Silvia,Urracci Ylenia,Sanna Giovanni,Gori Stefania,De Placido Sabino,Garrone Ornella,Fabi Alessandra,Barone Carla,Tamberi Stefano,Bighin Claudia,Puglisi Fabio,Moretti Gabriella,Arpino Grazia,Ballestrero Alberto,Poggio Francesca,Lambertini Matteo,Montemurro Filippo,Bruzzi Paolo

Funder

Novartis Pharmaceuticals Corp

Publisher

Elsevier BV

Subject

Oncology

Reference24 articles.

1. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO Clinical Practice Guideline focused update;Burstein;J Clin Oncol,2019

2. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Cardoso;Ann Oncol,2019

3. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years;Pan;N Engl J Med,2017

4. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial;Davies;Lancet,2013

5. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer;Gray;Proc Am Soc Clin Oncol,2013

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-07

2. Systemic Therapy in Breast Cancer;American Society of Clinical Oncology Educational Book;2024-06-01

3. Treatment and survival of patients diagnosed with high-risk HR+/HER2− breast cancer in the Netherlands: a population-based retrospective cohort study;ESMO Open;2024-05

4. Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis;European Journal of Cancer;2024-05

5. Racial and Ethnic Disparities in European Breast Cancer Clinical Trials;Cancers;2024-04-29